MPNs

Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.

In an analysis comparing real-life outcomes, interferon-a demonstrated more profound hematologic responses compared with hydroxyurea in select patients with myeloproliferative neoplasms. Additionally, molecular responses to therapy were limited to those patients who received IFN-a.

A new phase III trial has demonstrated that a novel extended-release formulation of anagrelide (Thromboreductin) is noninferior to immediate-release anagrelide in reducing platelet counts in patients with essential thrombocythemia.

Srdan Verstovsek, MD, PhD, discusses the use of interferon in MPNs, including essential thrombocythemia, polycythemia vera, and myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.

Diagnosis, risk stratification, and the management of patients with polycythemia vera and myelofibrosis have all been significantly improved by the inclusion of a greater understanding of the clinical and molecular characteristics of these 2 different myeloproliferative neoplasms, according to Abdulraheem Yacoub, MD.

Genomic testing could increasingly be utilized to guide treatment decisions for Veteran patients with cancer. Two recent announcements confirm an emerging focus from Veterans Affairs on genetic testing that provides more informed and tailored cancer care for US Veterans.

Abdulraheem Yacoub, MD, discusses the development of interferon and its current role in the management of patients with MPNs.

The highly selective JAK2 inhibitor fedratinib has received a priority review designation by the FDA as a treatment for patients with myelofibrosis. The designation was granted based on findings from the phase III JAKARTA and phase II JAKARTA-2 trials.

Jean-Jacques Kiladjian, MD, PhD, discusses 2 clinical trials evaluating the use of ruxolitinib in patients with polycythemia vera and myelofibrosis.

Jean-Jacques Kiladjian, MD, PhD, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera still remained on treatment with ruxolitinib.

Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.

Angela G. Fleischman, MD, PhD, discusses a clinical trial at her institution investigating the JAK1 inhibitor itacitinib in patients with MF. She also highlights other recent advancements for patients with MF, as well as advancements in other MPNs such as ET and PV.

A phase Ib dose-finding study has established the maximum safe starting dose of ruxolitinib to be 10 mg twice daily in treating myelofibrosis in patients with low initial platelet counts.

The American Society of Hematology has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.

Gabriela S. Hobbs, MD, discusses recent advances in the treatment of myelofibrosis and other MPNs, as well as clinical trials she is currently working on in this space.

Srdan Verstovsek, MD, PhD, discusses the current treatment landscape for patients with essential thrombocytopenia and polycythemia vera and shared details of ongoing clinical trials in the field.

Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis.

John O. Mascarenhas, MD, discusses with&nbsp;<em>Targeted Oncology&nbsp;</em>the&nbsp;recent advancements being made in the treatment of patients with advanced myelofibrosis and highlights some of the unmet needs that still exist within this space.

Jean-Jaques Kiladjian, MD, PhD, discusses how the results from the RESPONSE trial impact patients with polycythemia vera.

Stephen Oh, MD, PhD,&nbsp;discusses the use of ruxolitinib in patients with myelofibrosis and PV, and emerging agents and next steps in the field of MPNs.

Patients with hydroxyurea resistant/intolerant polycythemia vera without palpable splenomegaly who were treated with ruxolitinib experienced a 3-fold increase in the likelihood of achieving hematocrit control over patients treated with physician&rsquo;s-choice therapy, with a majority of those patients maintaining their response at 80 weeks, according to findings of a phase III prospective trial.

Harry P. Erba, MD, PhD, recently talked about the treatment considerations and decisions he makes when treating patients with primary myelofibrosis and polycythemia vera. Erba explained his treatment decisions for patients with myeloproliferative neoplasms based on 2 case scenarios to a group during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Srdan Verstovsek, MD, PhD,&nbsp;discusses the second-line use of ruxolitinib in patients with in PV and additional benefits with the agent as more data become available.

Beginning ruxolitinib (Jakafi) therapy at lower doses may limit the anemia frequently seen early in treatment in patients with myelofibrosis while still providing clinical benefits like improvements in splenomegaly, according to the results of a 24-week open-label phase II dose escalation study.